Unknown

Dataset Information

0

Enzymatically active ADAMTS13 variants are not inhibited by anti-ADAMTS13 autoantibodies: a novel therapeutic strategy?


ABSTRACT: ADAMTS13 (a disintegrin and metalloprotease with thrombospondin motifs), a circulating multidomain zinc metalloprotease of the reprolysin subfamily, is critical for preventing von Willebrand factor-platelet interaction under high shear stress conditions. A deficiency of the protease, due to mutations in the ADAMTS13 gene or the presence of antibodies that inhibit the activity of the protease, causes thrombotic thrombocytopenic purpura (TTP). Plasma therapy, the conventional therapy for TTP, may cause serious adverse reactions and is ineffective in some patients. In order to develop new strategies for improving the diagnosis and treatment of TTP, we produced a series of truncated ADAMTS13 proteins in mammalian cells and analyzed their binding with and suppression by the IgG derived from the TTP patients. The results revealed that truncation of the ADAMTS13 protein at its cysteine-rich region eliminated its recognition by the antibodies without abolishing its von Willebrand factor-cleaving activity. This raises the possibility that resistant ADAMTS13 variants may be exploited to circumvent inhibitory antibodies that cause TTP.

SUBMITTER: Zhou W 

PROVIDER: S-EPMC2582217 | biostudies-literature | 2005 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Enzymatically active ADAMTS13 variants are not inhibited by anti-ADAMTS13 autoantibodies: a novel therapeutic strategy?

Zhou Wenhua W   Dong Lingli L   Ginsburg David D   Bouhassira Eric E EE   Tsai Han-Mou HM  

The Journal of biological chemistry 20051003 48


ADAMTS13 (a disintegrin and metalloprotease with thrombospondin motifs), a circulating multidomain zinc metalloprotease of the reprolysin subfamily, is critical for preventing von Willebrand factor-platelet interaction under high shear stress conditions. A deficiency of the protease, due to mutations in the ADAMTS13 gene or the presence of antibodies that inhibit the activity of the protease, causes thrombotic thrombocytopenic purpura (TTP). Plasma therapy, the conventional therapy for TTP, may  ...[more]

Similar Datasets

| S-EPMC3208768 | biostudies-literature
| S-EPMC4563118 | biostudies-literature
| S-EPMC7354404 | biostudies-literature
| S-EPMC5355275 | biostudies-literature
| S-EPMC6054987 | biostudies-literature
| S-EPMC9631689 | biostudies-literature
| S-EPMC2930958 | biostudies-literature
| S-EPMC10307883 | biostudies-literature
| S-EPMC9376927 | biostudies-literature
| S-EPMC3642332 | biostudies-literature